Goldman Sachs’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-134
| Closed | -$56.5K | – | 4935 |
|
|
2023
Q1 | $56.5K | Sell |
134
-4
| -3% | -$1.69K | ﹤0.01% | 4747 |
|
|
2022
Q4 | $167K | Sell |
138
-11
| -7% | -$13.3K | ﹤0.01% | 4554 |
|
|
2022
Q3 | $118K | Sell |
149
-77
| -34% | -$61K | ﹤0.01% | 4881 |
|
|
2022
Q2 | $324K | Buy |
226
+44
| +24% | +$63.1K | ﹤0.01% | 4652 |
|
|
2022
Q1 | $380K | Sell |
182
-56
| -24% | -$117K | ﹤0.01% | 4751 |
|
|
2021
Q4 | $1.17M | Buy |
238
+4
| +2% | +$19.6K | ﹤0.01% | 3907 |
|
|
2021
Q3 | $1.47M | Buy |
234
+76
| +48% | +$476K | ﹤0.01% | 3716 |
|
|
2021
Q2 | $1.48M | Sell |
158
-8
| -5% | -$75.1K | ﹤0.01% | 3739 |
|
|
2021
Q1 | $1.44M | Buy |
166
+31
| +23% | +$269K | ﹤0.01% | 3653 |
|
|
2020
Q4 | $1.03M | Buy |
135
+79
| +141% | +$602K | ﹤0.01% | 3440 |
|
|
2020
Q3 | $369K | Buy |
56
+5
| +10% | +$32.9K | ﹤0.01% | 3800 |
|
|
2020
Q2 | $378K | Buy |
+51
| New | +$378K | ﹤0.01% | 3723 |
|
|
2019
Q2 | – | Sell |
-15
| Closed | -$246K | – | 4174 |
|
|
2019
Q1 | $246K | Buy |
+15
| New | +$246K | ﹤0.01% | 3811 |
|
|
2018
Q4 | – | Sell |
-6
| Closed | -$81K | – | 4076 |
|
|
2018
Q3 | $81K | Buy |
+6
| New | +$81K | ﹤0.01% | 3983 |
|
|
2016
Q2 | – | Sell |
-18
| Closed | -$194K | – | 4512 |
|
|
2016
Q1 | $194K | Buy |
+18
| New | +$194K | ﹤0.01% | 3787 |
|